On Jun 29, 2018 Raymond James Analyzed ChemoCentryx (NASDAQ:CCXI) with $18 Target.

June 29, 2018 - By Alex Paulin

ChemoCentryx, Inc. (NASDAQ:CCXI) Corporate Logo

During 2018 Q1 the big money sentiment decreased to 1. That’s change of 0.30, from 2017Q4’s 1.3. 10 investors sold all, 36 reduced holdings as ChemoCentryx, Inc. ratio dropped. 22 rose holdings while 24 funds took holdings. Funds hold 24.22 million shares thus 3.03% more from 2017Q4’s 23.51 million shares.

13,066 were accumulated by Barclays Public Limited Com. Credit Suisse Ag has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Renaissance Technology Limited Liability accumulated 769,281 shs or 0.01% of the stock. 2,817 were reported by Sei Invs. Jacobs Levy Equity Mngmt holds 0% or 15,708 shs in its capital. D E Shaw Communications holds 0.01% of its capital in ChemoCentryx, Inc. (NASDAQ:CCXI) for 352,867 shs. Td Asset Incorporated has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Morgan Stanley reported 93,203 shs. Tower Lc (Trc) accumulated 1,962 shs or 0% of the stock. Citadel Advisors Limited Liability Company holds 18,829 shs or 0% of its capital. Bancorporation Of America De invested 0% of its capital in ChemoCentryx, Inc. (NASDAQ:CCXI). Walleye Trading has 14,400 shs for 0% of their capital. Wells Fargo & Mn holds 0% of its capital in ChemoCentryx, Inc. (NASDAQ:CCXI) for 52,971 shs. Connor Clark Lunn Invest Mgmt Ltd holds 0% or 56,739 shs in its capital. Rhumbline Advisers stated it has 23,578 shs or 0% of all its holdings.

ChemoCentryx, Inc. had 8 selling transactions and 0 insider buys since May 1, 2018. This’s net activity of $6.04 million. $550,858 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) shs were sold by Schall Thomas J.. 1,366 shs valued at $15,709 were sold by KANAYA SUSAN M on Wednesday, May 2.

What Price Target Has Raymond James Given ChemoCentryx (NASDAQ:CCXI)

ChemoCentryx (NASDAQ:CCXI) coverage has initiated by Research professionals at Raymond James. It was set “Strong Buy” rating and a $18 target price on Thursday morning. PT indicates a potential upside of 31.29 % from the company’s current price.

ChemoCentryx, Inc. (NASDAQ:CCXI) Ratings Coverage

A total of 4 analysts rate ChemoCentryx (NASDAQ:CCXI) as follows: 4 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:CCXI) has 4 ratings reports on Jun 29, 2018 according to StockzIntelligence. On Tuesday, March 13 the stock has “Overweight” rating by JP Morgan.

The stock decreased 1.93% or $0.27 during the last trading session, hitting $13.71.Currently ChemoCentryx, Inc. is uptrending after 83.50% change in last June 29, 2017. CCXI has also 101,216 shares volume. The stock outperformed the S&P 500 by 70.93%.

ChemoCentryx, Inc. (NASDAQ:CCXI) is expected to report earnings on August, 14., Zacks reports. earnings per share of $-0.25 is 31.58 % down from 2017’s $-0.19 EPS. 31.58 % negative EPS growth is what Wall Street’s predicts after $-0.19 reported EPS previous quarter.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States.The firm is worth $673.85 million. The firm targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies.The P/E ratio is 47.28. The Company’s lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor , is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).

More recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were announced by Seekingalpha.com, Benzinga.com and Finance.Yahoo.com. The first one has “InflaRx: Buy The Dip” as a title and was announced on June 29, 2018. The next is “35 Stocks Moving In Monday’s Mid-Day Session” on June 04, 2018. And last was announced on June 14, 2018, called “4 Top-Ranked Nasdaq Stocks That Have Doubled This Year”.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.